Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an RNA 'Message' reprogram the immune system to stop autoimmune blood disorders?

NCT ID NCT07765966

Disease control Sponsor: RiboX Therapeutics Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This early-stage trial is testing an experimental therapy called RXIM002 in adults with relapsed or refractory autoimmune cytopenias, including immune thrombocytopenia (ITP). The therapy uses a special RNA molecule to instruct the body to produce CAR T cells that target and potentially calm the immune cells attacking blood cells. The study aims to evaluate the safety, tolerability, and preliminary effectiveness of this approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RXIM002, an experimental RNA-based therapy that instructs the body to make CAR T cells targeting CD19
What this could lead to
If successful, this could lead to a new treatment option for people with autoimmune cytopenias that have not responded to standard therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so safety and effectiveness are not yet established. There are risks of side effects, and the therapy may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 27 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2027

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18-75 years of age * Diagnosed with primary ITP * Relapsed or refractory ITP Exclusion Criteria: * Allergy or hypersensitivity to messenger ribonucleic acid (mRNA) vaccines or other RNA-LNP products * Any active infection * Heart failure, reduced kidney function, or liver abnormalities

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immune thrombocytopenia (ITP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Purpura, Thrombocytopenic, Idiopathic Recurrence thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immune thrombocytopenia (ITP) Relapsed or refractory autoimmune cytopenias

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.